| Literature DB >> 22719751 |
Melanie Ganz1, Marleen de Bruijne, Erik B Dam, Paola Pettersen, Morten A Karsdal, Claus Christiansen, Mads Nielsen.
Abstract
Abdominal aortic calcifications (AACs) correlate strongly with coronary artery calcifications and can be predictors of cardiovascular mortality. We investigated whether size, shape, and distribution of AACs are related to mortality and how such prognostic markers perform compared to the state-of-the-art AC24 marker introduced by Kauppila. Methods. For 308 postmenopausal women, we quantified the number of AAC and the percentage of the abdominal aorta that the lesions occupied in terms of their area, simulated plaque area, thickness, wall coverage, and length. We analysed inter-/intraobserver reproducibility and predictive ability of mortality after 8-9 years via Cox regression leading to hazard ratios (HRs). Results. The coefficient of variation was below 25% for all markers. The strongest individual predictors were the number of calcifications (HR = 2.4) and the simulated area percentage (HR = 2.96) of a calcified plaque, and, unlike AC24 (HR = 1.66), they allowed mortality prediction also after adjusting for traditional risk factors. In a combined Cox regression model, the strongest complementary predictors were the number of calcifications (HR = 2.76) and the area percentage (HR = -3.84). Conclusion. Morphometric markers of AAC quantified from radiographs may be a useful tool for screening and monitoring risk of CVD mortality.Entities:
Year: 2012 PMID: 22719751 PMCID: PMC3375152 DOI: 10.1155/2012/459286
Source DB: PubMed Journal: Int J Biomed Imaging ISSN: 1687-4188
Figure 1A manual annotation of an X-ray: in blue we see distinct vertebra points, in green the aorta wall, and in red the calcifications.
Figure 2A schematic view of AC24. The AC24 is constructed by projecting the AAC to the corresponding aorta wall.
Figure 3Left: a schematic visualization of a plaque similar to what can be seen in histology. The calcified plaque (light blue) is surrounded by an area of necrotic tissue (gray). Right: the simulated area tries to imitate the area of necrotic tissue (green) as seen in histology by a morphological dilation (visualized by circles) of the calcified plaque (light blue).
Figure 4A schematic overview of the study population.
The mean and standard deviation of the measured metabolic and physical markers.
| Physical/metabolic markers | Population ( | Survivors ( | Deceased (all-cause) ( |
|---|---|---|---|
| Age (years) | 60.3 ± 7.5 | 59.3 ± 7.1 | 65.6 ± 7.0 |
| Waist (cm) | 80.7 ± 10.9 | 80.2 ± 9.9 | 83.1 ± 12.4 |
| Waist-to-hip ratio | 0.80 ± 0.08 | 0.80 ± 0.08 | 0.83 ± 0.10 |
| Body mass index (kg/m2) | 24.7 ± 3.9 | 24.7 ± 3.8 | 25.1 ± 4.6 |
| Smoking (%) | 37 | 33 | 58 |
| Systolic BP (mm Hg) | 127 ± 21 | 125 ± 20 | 136 ± 26 |
| Diastolic BP (mm Hg) | 77 ± 10 | 76 ± 10 | 77 ± 11 |
| Hypertension (%) | 16 | 15 | 17 |
| Glucose (mmol/L) | 5.44 ± 1.27 | 5.37 ± 0.99 | 5.79 ± 2.17 |
| Total cholesterol (mmol/L) | 6.44 ± 1.19 | 6.36 ± 1.14 | 6.85 ± 1.33 |
| Triglycerides (mmol/L) | 1.24 ± 0.75 | 1.15 ± 0.56 | 1.69 ± 1.25 |
| LDL-C (mmol/L) | 2.89 ± 0.82 | 2.85 ± 0.80 | 3.07 ± 0.93 |
| HDL-C (mmol/L) | 1.77 ± 0.48 | 1.77 ± 0.44 | 1.74 ± 0.62 |
| ApoB/ApoA | 0.57 ± 0.18 | 0.56 ± 0.17 | 0.64 ± 0.23 |
| Lp (a) (mg/dL) | 21.4 ± 21.7 | 21.9 ± 22.0 | 18.4 ± 19.8 |
| EU SCORE | 2.60 ± 2.58 | 2.16 ± 2.12 | 4.73 ± 3.45 |
| Framingham | 14.75 ± 3.54 | 14.21 ± 3.46 | 17.31 ± 2.74 |
Figure 5An X-ray of a participant in the EPI followup population. (a): an annotation by a radiologist. (b): a second annotation by the same radiologist. (c): an annotation done by another radiologist.
The inter- and intraobserver mean coefficients of variation for the AAC markers based on the inter-intra-observer test population.
| Inter-intra-observer population | Interobserver CV % | Intraobserver CV % |
|---|---|---|
| Area % | 24.1 | 24.9 |
| Sim. area % | 24.9 | 20.3 |
| Thickness % | 16.8 | 14 |
| Wall % | 13.0 | 12.5 |
| Length % | 13.0 | 12.5 |
| NCD | 19.4 | 16.6 |
The mean ± one standard deviation of all the imaging markers stratified for the different subsets of patients. NCD# stands for number of calcifications.
| All ( | Survivors ( | CVD ( | Cancer ( | CVD/Can ( | Other ( | All-cause ( | |
|---|---|---|---|---|---|---|---|
| AC24 | 1.67 ± 2.55 | 1.35 ± 2.34 | 3.50 ± 2.35 | 3.41 ± 3.23 | 3.45 ± 2.86 | 1.35 ± 2.36 | 3.23 ± 2.86 |
| Area % (%) | 0.6 ± 1.2 | 0.5 ± 1.1 | 1.0 ± 0.9 | 1.6 ± 1.8 | 1.3 ± 1.5 | 0.5 ± 1.1 | 1.2 ± 1.5 |
| Sim. area % (%) | 11 ± 17 | 8.9 ± 15.7 | 24 ± 16 | 25 ± 24 | 25 ± 21 | 8.7 ± 15.5 | 23 ± 21 |
| Thickness % (%) | 11 ± 20 | 9.0 ± | 17 ± 16 | 25 ± 28 | 21 ± 24 | 8.7 ± 19 | 20 ± 24 |
| Wall % (%) | 1.03 ± 1.83 | 0.79 ± 1.64 | 2.08 ± 1.70 | 2.51 ± 2.68 | 2.33 ± 2.30 | 0.80 ± 1.63 | 2.16 ± 2.27 |
| Length % (%) | 7.5 ± 12.8 | 6.0 ± 11.7 | 15.4 ± 11.2 | 17.3 ± 17.6 | 16.5 ± 15.1 | 5.9 ± 11.6 | 15.4 ± 15.0 |
| NCD# | 3.8 ± 7.7 | 2.6 ± 6.4 | 8.5 ± 6.5 | 11.6 ± 13.4 | 10.3 ± 11.0 | 2.6 ± 6.3 | 9.6 ± 10.8 |
The relative risk per standard deviation increase in marker values stratified into death cause and adjusted for physical/metabolic markers, EU SCORE, and Framingham score, respectively. The symbols *, **, and *** denote the significance corresponding to P < 0.05, P < 0.01, and P < 0.001, respectively. NCD# stands for number of calcifications.
| Hazard ratio not adjusted | Hazard ratio bioadjusted | Hazard ratio SCORE-adjusted | Hazard ratio Framingham-adjusted | |
|---|---|---|---|---|
| AC24 | ||||
| CVD | 1.66 (1.25–2.19)*** | NS | 1.38 (1.02–1.86)* | NS |
| CVD/cancer | 1.64 (1.35–2.00)*** | 1.31 (1.06–1.63)* | 1.40 (1.13–1.72)** | 1.29 (1.02–1.63)* |
|
| ||||
| Area% | ||||
| CVD | 1.60 (1.16–2.20)** | NS | NS | NS |
| CVD/cancer | 1.68 (1.36–2.09)*** | 1.32 (1.04–1.66)* | 1.47 (1.16–1.86)** | 1.34 (1.04–1.72)* |
|
| ||||
| Sim. area% | ||||
| CVD | 2.96 (1.76–4.99)*** | 2.00 (1.15–3.49)* | 2.46 (1.41–4.27)** | 2.27 (1.26–4.09)** |
| CVD/cancer | 2.37 (1.73–3.25)*** | 1.68 (1.20–2.34)** | 1.96 (1.40–2.73)*** | 1.79 (1.26–2.54)** |
|
| ||||
| Thickness% | ||||
| CVD | NS | NS | NS | NS |
| CVD/cancer | 1.45(1.20–1.75)*** | NS | 1.27 (1.04–1.55)* | NS |
|
| ||||
| Wall% | ||||
| CVD | 1.50 (1.16–1.95)** | NS | NS | NS |
| CVD/cancer | 1.60 (1.34–1.91)*** | 1.26 (1.04–1.53)* | 1.42 (1.17–1.73)*** | 1.30 (1.05–1.62)* |
|
| ||||
| Length% | ||||
| CVD | 1.55 (1.18–2.04)** | NS | NS | NS |
| CVD/cancer | 1.61 (1.34–1.95)*** | 1.26 (1.03–1.55)* | 1.42 (1.16–1.73)*** | 1.29 (1.03–1.62)* |
|
| ||||
| NCD# | ||||
| CVD | 2.44 (1.72–3.48)*** | 1.76 (1.20–2.60)** | 2.20 (1.48–3.26)*** | 2.04 (1.34–3.12)*** |
| CVD/cancer | 2.28(1.79–2.90)*** | 1.69 (1.30–2.21)*** | 2.00 (1.53–2.62)*** | 1.86 (1.40–2.47)*** |
The individual hazard ratios for the markers in the CVD and the CVD/cancer group as well as two Cox regression elimination models. First the nonadjusted hazard ratios from Table 2 are stated again, and then two elimination models are shown. The symbols *, **, and *** denote the significance corresponding to P < 0.05, P < 0.01, and P < 0.001, respectively. #NCD stands for number of calcifications.
| CVD: | CVD Elim.: | CVD/cancer: | CVD/cancer Elim.: | |
|---|---|---|---|---|
| AC24 | 1.66*** | — | 1.64*** | — |
| Area % | 1.60** | −3.84*** | 1.68*** | 2.39*** |
| Sim. area % | 2.96*** | — | 2.37*** | — |
| Thickness % | 1.32 | — | 1.45*** | — |
| Wall % | 1.50** | — | 1.60*** | — |
| Length % | 1.55** | — | 1.61*** | — |
| NCD# | 2.44*** | 2.76*** | 2.28*** | 1.88*** |